With streamlined, “sitevisitless” CCSG review in place, cancer centers remained stable in 2025

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Earlier this month, NCI released a new Cancer Center Support Grant Notice of Funding Opportunity. Except for the elimination of the Plan to Enhance Diversity component and lengthening of the Shared Resource write-ups from three to six pages, the guidelines are essentially unchanged. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Richard J. Jones, MD
Professor of oncology and medicine, Director, Bone Marrow Transplantation Program, Co-Director, Hematologic Malignancies Programs, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins
Table of Contents

YOU MAY BE INTERESTED IN

Growing up in inner-city Detroit, Otis Brawley had a thriving community made up of his parents, Jesuit priests, friends, and neighbors encouraging him that he could do anything he put his mind to. 
As NCI paylines drop to 4%, cancer centers are tapping into their institutional funds to provide “bridge funding,” typically in $50,000 to $100,000 increments, to enable investigators to keep their labs open until better times return—next year God willing.
Richard J. Jones, MD
Professor of oncology and medicine, Director, Bone Marrow Transplantation Program, Co-Director, Hematologic Malignancies Programs, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login